Press Release
16 November 2026 12:00:00 CET

Oncorena appoints Mikael Engblom as Chief Financial Officer

Lund, Sweden, November 16, 2026 – Oncorena, a Swedish pharmaceutical company developing a novel treatment for metastatic kidney cancer, today announces the appointment of Mikael Engblom as Chief Financial Officer (CFO), effective November 16, 2026. He succeeds Pål Falck, who will focus on his role as Chief Business Officer (CBO). The appointment strengthens Oncorena's executive management team as the company prepares for its next phase of development and commercial opportunities.

Mikael Engblom brings extensive financial leadership experience, with a strong track record in the Life Science sector and more than ten years as CFO of both publicly listed and privately held companies. He most recently served as CFO of Axel Arigato and has previously held senior financial leadership positions at BICO Group and Vitrolife, where he served as CFO for ten years.

During Mikael's tenure at Vitrolife, he played an important role in supporting the company's international expansion and growth, including acquisitions, corporate governance and financial reporting. His experience in building scalable financial organizations and navigating the requirements of publicly listed companies will be valuable as Oncorena advances its development strategy.

Since March 2026, Åsa Hillsten has served as Investor Relations and Communications Advisor to Oncorena. Mikael Engblom and Åsa Hillsten previously worked together as advisors to BICO Group in 2022, bringing an established professional relationship and complementary expertise in finance, investor relations and corporate communications to Oncorena.

"We are delighted to welcome Mikael Engblom as the new CFO at Oncorena AB," says Börje Haraldsson, CEO of Oncorena. "As an experienced CFO, he will strengthen our executive team as the company continues to grow. We are indebted to Pål Falck who has served as both CFO and CBO for several years. Now, Pål will focus on his role as CBO to build a business organization founded on scientific evidence.",

The appointment forms part of Oncorena's continued efforts to strengthen its organizational capabilities as the company advances the development of its lead drug candidate, ONC175, and prepares for future commercial opportunities.

"I look forward to joining Oncorena at this important stage of its development," says Mikael Engblom. "The company has a compelling scientific foundation and an opportunity to address significant unmet medical needs in kidney cancer. I am excited to contribute my experience in financial leadership, corporate development and capital markets as Oncorena prepares for its next phase."

About Mikael Engblom

Mikael Engblom has more than 20 years of experience in finance and business management, including CFO positions at Vitrolife AB (publ), BICO Group AB (publ) and Axel Arigato AB. During his ten years as CFO of Vitrolife, he was responsible for finance, investor relations, corporate governance, legal affairs and IT, and contributed to the company's significant growth and international expansion. He holds a Master of Science in Business Administration from the University of Gothenburg.

About Oncorena

Oncorena is a Swedish pharmaceutical company developing innovative treatments for patients with advanced kidney cancer. The company's lead drug candidate, ONC175, is being evaluated in clinical development, with the ambition to address significant unmet medical needs and improve treatment options for patients with metastatic renal cancer.

For more information, please visit www.oncorena.se.

For further information, please contact:

Börje Haraldsson, CEO Oncorena
Mail: borje.haraldsson@oncorena.com
Phone: +46 70-267 95 44